BioPharma

Strategic oversight and regulatory navigation in the pharmaceutical industry rely on an integrated approach to drug development consulting, ensuring that global clinical pipelines reach the market efficiently.

Examining the shift from transactional outsourcing to collaborative alliances, where shared risk and integrated data drive clinical success in the 2026 pharmaceutical landscape.

Axplora has reached a key milestone in its ongoing investment strategy, advancing a $60 million programme dedicated to strengthening HPAPI manufacturing capabilities at its Farmabios site in Gropello Cairoli. The latest development involves the construction of a new 4,500...

The supplemental Biologics License Application - sBLA for Enhertu - trastuzumab deruxtecan by AstraZeneca and Daiichi Sankyo has been accepted as well as granted Priority Review in the U.S. when it comes to the treatment of adult patients with...

Sanofi has committed up to $1.53 billion to obtain global rights to a novel therapy from Sino Biopharmaceutical, adding a first-in-class JAK/ROCK inhibitor to its hematology and immunology pipeline. The French pharmaceutical group will make an upfront payment of...

On February 17, 2026, GSK plc announced that the European Commission approves Exdensur - depemokimab in two indications - As an add-on maintenance treatment when it comes to critical asthma with type 2 inflammation that stands characterised by a blood eosinophil...

Modern biopharmaceutical facilities are leveraging advanced automation to enhance the production of complex biologics, ensuring real-time quality control and operational efficiency.